Mangoceuticals, Inc.

What they do

Mangoceuticals markets compounded prescription products directly to consumers, with a focus on men's health, and relies on third parties to prescribe and compound its products. The company sells through its MangoRx brand and operates consumer-facing websites, including www.mangoceuticals.com. It describes itself as having a limited operating history with limited product output and limited revenues to date.

Revenue drivers

• Compounded men's health prescription products (MangoRx) — The core business is compounded prescription products dispensed to consumers, marketed under the MangoRx brand; this is the only revenue-generating line disclosed in the filing excerpts.
• Direct-to-consumer telehealth platform — Products are sold directly to consumers rather than through retail channels, making consumer acquisition and the company's websites the primary route to revenue.
• Third-party prescribing and compounding arrangements — The company depends on third parties to prescribe and compound its products; these relationships determine whether orders can be filled, and the filings flag related-party reliance as a risk.

Recent performance

Revenue has declined from $731,493 in 2023 to $615,873 in 2024 and $456,021 in 2025. Full-year net loss widened to $20.6 million in 2025 from $8.7 million in 2024, with diluted EPS of -$2.17. Operating cash flow was negative $5.9 million in 2025, compared with negative $4.9 million in 2024. The most recent quarters were $84,246 (September 2025), $94,360 (December 2025), $67,864 (March 2026) and $68,757 (June 2026). At June 30, 2026, the company reported $228,688 of cash and equivalents against $1.6 million of total liabilities, with $12.5 million of shareholder equity.

Strategy

The filings describe a strategy centered on expanding and growing operations and successfully marketing the company's products. Management highlights its ability to build and maintain its brand, increase sales, and expand operations as core priorities. The company also cites an ability to protect intellectual property and to attract and retain key personnel as factors in executing its plan. No specific new investment programs or capital commitments are described in the excerpts provided.

Risks

• Going-concern and funding risk — The company repeatedly cites its need for additional funding, the terms of such funding, and dilution caused thereby, alongside negative operating cash flow.
• Regulatory risk on compounded products — The company states that its products have not been and will not be approved by the FDA, and that the FDA may determine its compounding does not fall within the Section 503A exemption from the FFDCA.
• Third-party dependence — The business depends on third parties to prescribe and compound its products, and on establishing and maintaining relationships with those third parties.
• Related-party reliance — The 10-K summary risk factors specifically flag significant reliance on related party transactions and the risks associated with those relationships and agreements.

Outlook

The excerpts provided do not include specific management guidance for future periods. The 10-K and 10-Q describe forward-looking statements tied to the company's ability to obtain additional funding, grow operations, market products and increase sales. Management also identifies competition, regulation of operations and products, and shipping and manufacturing delays as factors that could affect results. Actual results may differ materially from these statements.